Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: Importance of the reference values

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages 1196-1203

  Touvier, Mathilde ^a   Deschasaux, Mélanie ^a   Montourcy, Marion ^a   Sutton, Angela ^b   Charnaux, Nathalie ^b   Kesse Guyot, Emmanuelle ^a   Fezeu, Léopold K ^a   Latino Martel, Paule ^a   Druesne Pecollo, Nathalie ^a   Malvy, Denis ^c   Galan, Pilar ^a   Hercberg, Serge ^a,d   Ezzedine, Khaled ^a,c   Souberbielle, Jean Claude ^e,f  

^a Sorbonne Paris Cité Research Center Nutritional Epidemiology Research Team Paris 13 University ^*  (France)

^b HÔPITAL JEAN VERDIER   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d AVICENNE HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; PARATHYROID HORMONE;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CALCIUM INTAKE; CAUCASIAN; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE VALUE; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL;

ADULT; AGE FACTORS; AGED; BODY WEIGHT; CALCIUM; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; DIAGNOSTIC TECHNIQUES, ENDOCRINE; EATING; FEMALE; HUMANS; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PARATHYROID HORMONE; REFERENCE VALUES; SEX FACTORS; VITAMIN D;

EID: 84898406133     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3349     Document Type: Article

References (33)

1. Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145-158.
2. Sahota O, Masud T, San P, Hosking DJ. Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis. Clin Endocrinol (Oxf). 1999;51(2):217-221.
3. van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA. Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J. 2013;165(5):655-664.
4. van der Wielen RP, Lowik MR, van den Berg H, et al. Serum vitamin D concentrations among elderly people in Europe. Lancet. 1995; 346(8969):207-210.
5. Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta. 2006;366(1-2):81-89.
6. Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzson L, Sig-urdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA. 2005; 294(18):2336-2341.
7. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997; 7(5):439-443.
8. Cavalier E, Delanaye P, Vranken L, et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant. 2012;27(5):1950-1956.
9. Souberbielle JC, Cormier C, Kindermans C, et al. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab. 2001;86(7):3086-3090.
10. Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier C. Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem. 2005;51(2):395-400.
11. Pilz S, Kienreich K, Drechsler C, et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interven-tional data from the GECOH study. J Clin Endocrinol Metab. 2012; 97(1):E75-E79.
12. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22(4):477-501.
13. Harris SS, Soteriades E, Coolidge JA, Mudgal S, Dawson-Hughes B. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab. 2000; 85(11):4125-4130.
14. Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S. Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest. 1985;76(1):370-373.
15. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):340-350.
16. Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of anti-oxidant vitamins and minerals. Arch Intern Med. 2004;164(21): 2335-2342.
17. Hercberg S. Table de composition SU.VI.MAX des Aliments. Les editions INSERM, Paris: Economica; 2005.
18. Rakel A, Brossard JH, Patenaude JV, et al. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol (Oxf). 2005;62(6):721-727.
19. Knudsen CS, Nexo E, Hojskov CS, Heickendorff L. Analytical validation of the Roche 25-OH Vitamin D Total assay. Clin Chem Lab Med. 2012;50(11):1965-1968.
20. Aloia JF, Talwar SA, Pollack S, Feuerman M, Yeh JK. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr. 2006;84(3):602-609.
21. Carter GD, Carter R, Jones J, Berry J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem. 2004;50(11):2195-2197.
22. Joly D, Drueke TB, Alberti C, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 2008;51(6):987-995.
23. La'ulu SL, Roberts WL. Performance characteristics of six intact parathyroid hormone assays. Am JClin Pathol. 2010;134(6):930-938.
24. Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Determinants of plasma PTH and their implication for defining a reference interval. Clin Endocrinol (Oxf). 2011;74(1):37-43.
25. el-Hajj FG, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA. The parathyroid hormone circadian rhythm is truly endoge-nous-a general clinical research center study. J Clin Endocrinol Metab. 1997;82(1):281-286.
26. Rejnmark L, LauridsenAL,VestergaardP, HeickendorffL, Andrea-sen F, Mosekilde L. Diurnal rhythm of plasma 1,25-dihydroxyvi-tamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism. Eur J Endocrinol. 2002;146(5):635-642.
27. Smith ER, Cai MM, McMahon LP, Holt SG. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin En-docrinol Metab. 2012;97(9):3357-3365.
28. Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C. The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. JClin Endocrinol Metab. 2003;88(8):3501-3504.
29. Koumakis E, Souberbielle JC, Sarfati E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with nor-mocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98(8):3213-3220.
30. Lundgren E, Hagstrom EG, Lundin J, et al. Primary hyperparathy-roidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World JSurg. 2002;26(8):931-936.
31. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70(2):345-350.
32. Holmes DT, Levin A, Forer B, Rosenberg F. Preanalytical influences on DPC IMMULITE 2000 intact PTH assays of plasma and serum from dialysis patients. Clin Chem. 2005;51(5):915-917.
33. Stepman HC, Vanderroost A, Van UK, Thienpont LM. Candidate reference measurement procedures for serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 by using isotope-dilution liquid chromatography-tandem mass spectrometry. Clin Chem. 2011; 57(3):441-448.